Release Date: 13/03/09 11:21 Summary: Unitholder Correspondence - Interim Report 2009 Price Sensitive: No Download Document 893.78KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%